Lifestyle or pharmacotherapy in cardio-metabolic disease prevention

Area of Science:

• Cardiology
• Metabolic Disorders
• Public Health

Background:

• Cardio-metabolic diseases (diabetes, hypertension, heart disease, stroke) are leading causes of premature death and severe multimorbidity worldwide.
• These conditions significantly increase all-cause mortality and reduce life expectancy.
• The rising prevalence of cardio-metabolic multimorbidity poses an unsustainable burden on healthcare systems.

Purpose of the Study:

• To highlight the limitations of a purely pharmacological approach to managing cardio-metabolic multimorbidity.
• To advocate for patient empowerment through lifestyle modifications as a primary or adjunctive strategy.

Main Methods:

• Literature review and synthesis of current evidence on cardio-metabolic disease management.
• Analysis of the risks and limitations associated with polypharmacy in multimorbidity.
• Emphasis on the benefits of lifestyle interventions.

Main Results:

• Polypharmacy in cardio-metabolic multimorbidity is associated with risks including improper prescribing, poor compliance, adverse effects, and increased costs.
• Lifestyle changes such as smoking cessation, improved diet, sleep hygiene, and physical activity are effective adjunctive or alternative strategies.
• Empowering patients with self-management through lifestyle adoption fosters independent living.

Conclusions:

• Healthcare systems cannot solely 'treat' the cardio-metabolic disease pandemic through medication.
• Lifestyle interventions are crucial for managing cardio-metabolic multimorbidity, improving patient outcomes, and reducing healthcare burdens.
• Promoting healthy lifestyles empowers individuals to live more independently with their conditions.